Rho(d) immune globulin intravenous (human) - Biologic Drug Details

Summary for rho(d) immune globulin intravenous (human)

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	3

Pharmacology for rho(d) immune globulin intravenous (human)

Mechanism of Action	Endogenous Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rho(d) immune globulin intravenous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rho(d) immune globulin intravenous (human) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for rho(d) immune globulin intravenous (human) Derived from Patent Text Search

No patents found based on company disclosures

Rho(d) immune globulin intravenous (human) Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Rho(D) Immune Globulin

Introduction

Rho(D) immune globulin (RhIG) is a biologic drug used to prevent and treat various medical conditions, including Rh isoimmunization in pregnant women and immune thrombocytopenic purpura (ITP). Here, we delve into the market dynamics and financial trajectory of this crucial medication.

Market Size and Growth

The global human Rho D immune globulin market is projected to experience significant growth. By 2033, the market is expected to reach USD 1.5 billion, growing at a Compound Annual Growth Rate (CAGR) of 6.3% from 2021 to 2033[1].

Key Drivers of Market Growth

Several factors are driving the growth of the Rho(D) immune globulin market:

Increasing Prevalence of Rh Incompatibility

The rising prevalence of Rh incompatibility, particularly in developing countries, is a major driver. Rh incompatibility can lead to hemolytic disease of the newborn (HDN), making preventive measures with RhIG crucial[1].

Advancements in Delivery Systems

The development of novel delivery systems such as subcutaneous and intranasal formulations is improving patient convenience and compliance, thereby driving market growth[1].

Rising Adoption of Prophylactic Treatment

The increasing adoption of prophylactic treatment regimens during pregnancy is creating new growth opportunities for market players[1].

Market Segmentation

The Rho(D) immune globulin market can be segmented based on several criteria:

Product Type

• Intramuscular Injections: Hold the largest market share due to their well-established efficacy, safety profile, and ease of administration.
• Intravenous Solutions: Used in high-risk situations such as after invasive procedures or in cases of heavy fetal-maternal hemorrhage.
• Subcutaneous Products: Gaining popularity due to their potential for self-administration and improved patient convenience[1].

Geographical Segmentation

• North America: Currently dominates the market due to the high prevalence of Rh incompatibility, well-established healthcare infrastructure, and favorable reimbursement policies.
• Europe: The second-largest market, with significant contributions from countries like Germany, France, and the UK.
• Asia-Pacific: Expected to witness the highest growth rate due to the large population base, increasing awareness about prenatal care, and improving access to healthcare services[1].

Mechanism of Action and Indications

RhIG works by preventing Rh isoimmunization through an immunologic blockade of Fc receptors within the reticuloendothelial system. Here are its key indications:

Prevention of Hemolytic Disease of the Newborn

RhIG is used to prevent the formation of anti-D antibodies in Rh-negative mothers carrying Rh-positive fetuses, thereby preventing HDN[2].

Treatment of Immune Thrombocytopenic Purpura

RhIG is administered intravenously to treat ITP in patients with Rh-positive blood, helping to increase platelet counts and reduce bleeding[2][5].

Administration and Monitoring

• Administration Routes: Intramuscular, intravenous, and subcutaneous.
• Monitoring: Patients should be monitored for systemic reactions, especially when using RhIG for ITP. Monitoring includes complete blood count, differential, direct antiglobulin test, and urinalysis[2].

Financial Trajectory

The financial outlook for the Rho(D) immune globulin market is promising:

Market Value

The global market is expected to reach USD 1.5 billion by 2033, with a CAGR of 6.3% from 2021 to 2033[1].

Revenue Streams

• The market benefits from the growing demand in emerging economies and the expanding access to prenatal care services.
• The development of long-acting and targeted delivery systems is expected to further boost revenue[1].

Challenges and Opportunities

While the market is growing, it faces several challenges and opportunities:

High Costs and Limited Reimbursement

The high cost of the medication and limited reimbursement policies in certain regions can hinder market growth[1].

Novel Formulations and Personalized Medicine

The exploration of novel formulations and routes of administration, along with the adoption of pharmacogenomics and personalized medicine, may provide new growth opportunities[1].

Industry Insights and Trends

Innovations in Biotechnology

Advances in medical biotechnology are driving the growth of the immunoglobulin market, including RhIG. These innovations improve patient outcomes and reduce adverse events[4].

Expanding Applications

The use of RhIG and other immunoglobulins is expanding beyond traditional indications, including autoimmune and immune-mediated disorders. This expansion is driven by new insights into the pathophysiology of these diseases[4].

Key Takeaways

• The Rho(D) immune globulin market is driven by the increasing prevalence of Rh incompatibility and advancements in delivery systems.
• Intramuscular injections hold the largest market share, but subcutaneous products are gaining popularity.
• North America and Europe are significant markets, with the Asia-Pacific region expected to show the highest growth rate.
• The market faces challenges such as high costs but is expected to benefit from novel formulations and personalized medicine approaches.

FAQs

1. What is Rho(D) immune globulin used for? Rho(D) immune globulin is used to prevent hemolytic disease of the newborn and to treat immune thrombocytopenic purpura (ITP) in patients with Rh-positive blood[2][5].

2. How is Rho(D) immune globulin administered? It can be administered via intramuscular, intravenous, and subcutaneous routes, each with specific indications and monitoring requirements[2].

3. What are the key drivers of the Rho(D) immune globulin market? The market is driven by the increasing prevalence of Rh incompatibility, advancements in delivery systems, and the rising adoption of prophylactic treatment regimens[1].

4. Which region dominates the Rho(D) immune globulin market? North America currently dominates the market due to its well-established healthcare infrastructure and favorable reimbursement policies[1].

5. What are the potential challenges for the Rho(D) immune globulin market? The market faces challenges such as high costs and limited reimbursement policies in certain regions, as well as the potential impact of alternative management strategies[1].

Sources:

1. DataHorizon Research - Human Rho D Immune Globulin Market Size, Share, Growth, Trends[1].
2. NCBI Bookshelf - Rho(D) Immune Globulin - StatPearls[2].
3. BioSpace - Immunoglobulin Market Size to Worth around USD 28.70 Bn by 2034[3].
4. BioSpace - Intravenous Immunoglobulin Market Experiencing Growth of 8.1% by 2034[4].
5. Mayo Clinic - Rho(d) immune globulin (injection route, intramuscular route, intravenous route)[5].